Triple Negative Breast Cancers – an obsolete entity?

Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells

(2023) Gamze Guney Eskiler et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA

(2023) Cheng Wang et al.   BIOORGANIC CHEMISTRY

Is the Androgen Receptor a viable target in triple negative breast cancer in 5 years?

(2023) Marina N. Sharifi et al.   Clinical Breast Cancer

Rare subtypes of triple negative breast cancer: Current understanding and future directions

(2023) Alexandra Thomas et al.   npj Breast Cancer

Evolution of low HER2 expression between early and advanced-stage breast cancer

(2022) Paolo Tarantino et al.   EUROPEAN JOURNAL OF CANCER

Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)

(2022) Beata Smolarz et al.   Cancers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

(2022) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons

(2022) Paolo Tarantino et al.   Cancer Discovery

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

(2022) Shom Goel et al.   Future Oncology

Recent advances in therapeutic strategies for triple-negative breast cancer

(2022) Yun Li et al.   Journal of Hematology & Oncology

Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness

(2022) Rinad Mahmoud et al.   Cancers

Update on triple‐negative breast cancers – highlighting subtyping update and treatment implication

(2022) Julia Y Tsang et al.   HISTOPATHOLOGY

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells

(2022) Edris Choupani et al.   PLoS One

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlation of Trop-2 expression with clinicopathological characteristics, sTILs, AR expression and outcome in primary TNBC.

(2021) Hava Izci et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

(2021) Ingrid A. Mayer et al.   JOURNAL OF CLINICAL ONCOLOGY

Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130

(2021) Sunil S Badve et al.   JNCI-Journal of the National Cancer Institute

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

(2021) Giacomo Barchiesi et al.   Frontiers in Oncology

The 2019 WHO classification of tumours of the breast

(2020) Puay Hoon Tan et al.   HISTOPATHOLOGY

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

(2020) Kimberly H. Allison et al.   JOURNAL OF CLINICAL ONCOLOGY

The repertoire of mutational signatures in human cancer

(2020) Ludmil B. Alexandrov et al.   NATURE

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2-Low Breast Cancer: Pathological and Clinical Landscape

(2020) Paolo Tarantino et al.   JOURNAL OF CLINICAL ONCOLOGY

Retinoblastoma protein expression and its predictors in triple-negative breast cancer

(2020) Jaymin M. Patel et al.   npj Breast Cancer

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

(2020) Javier Cortes et al.   LANCET

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

(2019) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Homologous recombination deficiency in triple negative breast cancer

(2019) Carmen Belli et al.   BREAST

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

(2019) Louis Fehrenbacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

(2018) Carsten Denkert et al.   LANCET ONCOLOGY

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database

(2018) Ki-Tae Hwang et al.   CLINICAL CANCER RESEARCH

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

(2017) David Cameron et al.   LANCET

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

(2016) H. Bonnefoi et al.   ANNALS OF ONCOLOGY

Molecular Classification of Triple-Negative Breast Cancer

(2016) Sung Gwe Ahn et al.   Journal of Breast Cancer

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

(2016) Serena Nik-Zainal et al.   NATURE

Biology and Management of Patients With Triple-Negative Breast Cancer

(2016) P. Sharma   ONCOLOGIST

Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status

(2016) He-Sheng Jiang et al.   Oncotarget

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Celebrating DNA’s Repair Crew

(2015) Thomas A. Kunkel   CELL

CCR 20th Anniversary Commentary: Divide and Conquer--Breast Cancer Subtypes and Response to Therapy

(2015) L. Pusztai et al.   CLINICAL CANCER RESEARCH

Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy

(2015) Christine S. Walsh   GYNECOLOGIC ONCOLOGY

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

(2015) Fergus J. Couch et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

(2015) Douglas F. Easton et al.   NEW ENGLAND JOURNAL OF MEDICINE

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

(2014) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

(2013) Brian D Lehmann et al.   JOURNAL OF PATHOLOGY

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial

(2011) Wolfgang Eiermann et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

(2011) D. G. Evans et al.   JOURNAL OF MEDICAL GENETICS

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

(2008) Nicholas C Turner et al.   EMBO JOURNAL

Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory

(2008) Sunil S. Badve et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial

(2008) P. Francis et al.   JNCI-Journal of the National Cancer Institute